Trade Mark Journal No.2026/041 9 October 2026

UK00004450416 24 September 2026 (40,42,44)

Image for mark UK00004450416 R
International priority date claimed: 2 April 2026 (United States of America) (99742150)
Class 40
Production of cell lines for use in the manufacture of biopharmaceuticals; Protein fabrication, production, and manufacture for others.
Class 42
Research and development of pharmaceutical products; Genetic engineering services utilizing a collection of genetic technologies for the rapid production of human antibodies; Genetic engineering services, namely, deletion and modification of genes for others, and production of genetically modified animals; Genetic research; Genetic engineering services for genes, cells, and animals using non-human embryonic stem cells (ES) and non-human embryo manipulation technology for rapid development of genetically modified non-human animals; Genetic engineering services, namely, the production of genetically-engineered antibodies for others; Genetic engineering services, namely, scientific laboratory services in the nature of the production of genetic sequences for others for scientific research and pharmaceutical research and development purposes; Scientific research in the field of genetics, genetic engineering, genetic sequencing, disease modeling, pharmacogenomics, and precision medicine; Providing medical and scientific research information in the fields of pharmaceuticals and genetics.
Class 44
Medical information; medical assistance services.

Regeneron Pharmaceuticals, Inc.

Representative: Appleyard Lees IP LLP